Low risk papillary thyroid cancer

Juan Brito Campana, Ian D Hay, John C. Morris

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Thyroid cancer is one of the fastest growing diagnoses; more cases of thyroid cancer are found every year than all leukemias and cancers of the liver, pancreas, and stomach. Most of these incident cases are papillary in origin and are both small and localized. Patients with these small localized papillary thyroid cancers have a 99% survival rate at 20 years. In view of the excellent prognosis of these tumors, they have been denoted as low risk. The incidence of these low risk thyroid cancers is growing, probably because of the use of imaging technologies capable of exposing a large reservoir of subclinical disease. Despite their excellent prognosis, these subclinical low risk cancers are often treated aggressively. Although surgery is traditionally viewed as the cornerstone treatment for these tumors, there is less agreement about the extent of surgery (lobectomy v near total thyroidectomy) and whether prophylactic central neck dissection for removal of lymph nodes is needed. Many of these tumors are treated with radioactive iodine ablation and thyrotropin suppressive therapy, which - although effective for more aggressive forms of thyroid cancer - have not been shown to be of benefit in the management of these lesions. This review offers an evidence based approach to managing low risk papillary thyroid cancer. It also looks at the future of promising alternative surgical techniques, non-surgical minimally localized invasive therapies (ethanol ablation and laser ablation), and active surveillance, all of which form part of a more individualized treatment approach for low risk papillary thyroid tumors.

Original languageEnglish (US)
Article numberg3045
JournalBMJ (Online)
Volume348
DOIs
StatePublished - Jun 16 2014

Fingerprint

Thyroid Neoplasms
Neoplasms
Disease Reservoirs
Neck Dissection
Thyroidectomy
Laser Therapy
Thyrotropin
Therapeutics
Liver Neoplasms
Pancreatic Neoplasms
Iodine
Stomach Neoplasms
Thyroid Gland
Leukemia
Ethanol
Survival Rate
Lymph Nodes
Papillary Thyroid cancer
Technology
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Low risk papillary thyroid cancer. / Brito Campana, Juan; Hay, Ian D; Morris, John C.

In: BMJ (Online), Vol. 348, g3045, 16.06.2014.

Research output: Contribution to journalArticle

@article{7a8d0f9de1164160b865dc3883426d94,
title = "Low risk papillary thyroid cancer",
abstract = "Thyroid cancer is one of the fastest growing diagnoses; more cases of thyroid cancer are found every year than all leukemias and cancers of the liver, pancreas, and stomach. Most of these incident cases are papillary in origin and are both small and localized. Patients with these small localized papillary thyroid cancers have a 99{\%} survival rate at 20 years. In view of the excellent prognosis of these tumors, they have been denoted as low risk. The incidence of these low risk thyroid cancers is growing, probably because of the use of imaging technologies capable of exposing a large reservoir of subclinical disease. Despite their excellent prognosis, these subclinical low risk cancers are often treated aggressively. Although surgery is traditionally viewed as the cornerstone treatment for these tumors, there is less agreement about the extent of surgery (lobectomy v near total thyroidectomy) and whether prophylactic central neck dissection for removal of lymph nodes is needed. Many of these tumors are treated with radioactive iodine ablation and thyrotropin suppressive therapy, which - although effective for more aggressive forms of thyroid cancer - have not been shown to be of benefit in the management of these lesions. This review offers an evidence based approach to managing low risk papillary thyroid cancer. It also looks at the future of promising alternative surgical techniques, non-surgical minimally localized invasive therapies (ethanol ablation and laser ablation), and active surveillance, all of which form part of a more individualized treatment approach for low risk papillary thyroid tumors.",
author = "{Brito Campana}, Juan and Hay, {Ian D} and Morris, {John C.}",
year = "2014",
month = "6",
day = "16",
doi = "10.1136/bmj.g3045",
language = "English (US)",
volume = "348",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Low risk papillary thyroid cancer

AU - Brito Campana, Juan

AU - Hay, Ian D

AU - Morris, John C.

PY - 2014/6/16

Y1 - 2014/6/16

N2 - Thyroid cancer is one of the fastest growing diagnoses; more cases of thyroid cancer are found every year than all leukemias and cancers of the liver, pancreas, and stomach. Most of these incident cases are papillary in origin and are both small and localized. Patients with these small localized papillary thyroid cancers have a 99% survival rate at 20 years. In view of the excellent prognosis of these tumors, they have been denoted as low risk. The incidence of these low risk thyroid cancers is growing, probably because of the use of imaging technologies capable of exposing a large reservoir of subclinical disease. Despite their excellent prognosis, these subclinical low risk cancers are often treated aggressively. Although surgery is traditionally viewed as the cornerstone treatment for these tumors, there is less agreement about the extent of surgery (lobectomy v near total thyroidectomy) and whether prophylactic central neck dissection for removal of lymph nodes is needed. Many of these tumors are treated with radioactive iodine ablation and thyrotropin suppressive therapy, which - although effective for more aggressive forms of thyroid cancer - have not been shown to be of benefit in the management of these lesions. This review offers an evidence based approach to managing low risk papillary thyroid cancer. It also looks at the future of promising alternative surgical techniques, non-surgical minimally localized invasive therapies (ethanol ablation and laser ablation), and active surveillance, all of which form part of a more individualized treatment approach for low risk papillary thyroid tumors.

AB - Thyroid cancer is one of the fastest growing diagnoses; more cases of thyroid cancer are found every year than all leukemias and cancers of the liver, pancreas, and stomach. Most of these incident cases are papillary in origin and are both small and localized. Patients with these small localized papillary thyroid cancers have a 99% survival rate at 20 years. In view of the excellent prognosis of these tumors, they have been denoted as low risk. The incidence of these low risk thyroid cancers is growing, probably because of the use of imaging technologies capable of exposing a large reservoir of subclinical disease. Despite their excellent prognosis, these subclinical low risk cancers are often treated aggressively. Although surgery is traditionally viewed as the cornerstone treatment for these tumors, there is less agreement about the extent of surgery (lobectomy v near total thyroidectomy) and whether prophylactic central neck dissection for removal of lymph nodes is needed. Many of these tumors are treated with radioactive iodine ablation and thyrotropin suppressive therapy, which - although effective for more aggressive forms of thyroid cancer - have not been shown to be of benefit in the management of these lesions. This review offers an evidence based approach to managing low risk papillary thyroid cancer. It also looks at the future of promising alternative surgical techniques, non-surgical minimally localized invasive therapies (ethanol ablation and laser ablation), and active surveillance, all of which form part of a more individualized treatment approach for low risk papillary thyroid tumors.

UR - http://www.scopus.com/inward/record.url?scp=84902602771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902602771&partnerID=8YFLogxK

U2 - 10.1136/bmj.g3045

DO - 10.1136/bmj.g3045

M3 - Article

C2 - 24935445

AN - SCOPUS:84902602771

VL - 348

JO - The BMJ

JF - The BMJ

SN - 0959-8146

M1 - g3045

ER -